AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. Shares in the brain drug developer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback